Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Metadata
Title
Pathogen inactivation of blood components: Current status and introduction of an approach using riboflavin as a photosensitizer
Author
Frank Corbin
Publication date
01-03-2002
Publisher
Springer-Verlag
Published in
International Journal of Hematology / Issue Special Issue 2/2002
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/BF03165125

Other articles of this Special Issue 2/2002

International Journal of Hematology 2/2002 Go to the issue

Update on Bleeding Disorders

Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura

Non-malignant Hematologic Disorders in Childhood

An approach to the diagnosis and treatment of bleeding disorders in infants

Update on Hypercoagulability

Targeted gene disruption of natural anticoagulant proteins in mice

Safety Issues in Blood & Blood Products Transfusion

The quest for quality blood banking program in the new millennium the American way

Treatment of Childhood Malignancy

Current concepts in treatment of childhood acute lymphoblastic leukemia

Understanding and Treatment of Acquired Aplastic Anemia

Aplastic anemia in the orient
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits